Tag: rivaroxaban

FDA approves expanded PAD indication for rivaroxaban plus aspirin

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease...

VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass...

“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev,...

Janssen submits new drug application to FDA for rivaroxaban to treat...

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the Food and Drug Administration...

ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in...

Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease...

VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients...

In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population...

Janssen applies to FDA for new indication to expand use of...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug...

Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or...

“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence...

Combining aspirin with rivaroxaban reduces risk equally in presence or absence...

In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients...

Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization

Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...